Implant-induced intraperitoneal inflammatory angiogenesis is attenuated by fluvastatin

Clinical and Experimental Pharmacology and Physiology

Volumn 38, Issue 4, 2011, Pages 262-268

  Araújo, Fernanda A ^a   Rocha, Monaliza A ^a   Ferreira, Mônica And ^a   Campos, Paula P ^a   Capettini, Luciano Sa ^a   Lemos, Virginia S ^a   Andrade, Silvia P ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

CCL2 JE; Implants; Nitric oxide; Tumour necrosis factor

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; FLUINDOSTATIN; HEMOGLOBIN; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOPEROXIDASE; N ACETYL BETA GLUCOSAMINIDASE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; IMPLANT; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SEDATION; UPREGULATION; WEIGHT REDUCTION;

ACETYLGLUCOSAMINIDASE; ANIMALS; BLOOD VESSELS; CHEMOKINE CCL2; FATTY ACIDS, MONOUNSATURATED; HEMOGLOBINS; IMPLANTS, EXPERIMENTAL; INDOLES; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; PERITONEUM; PERITONITIS; PEROXIDASE; POLYURETHANES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953041971     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2011.05496.x     Document Type: Article

References (35)

1. Menzies D, Ellis H. Intestinal obstruction from adhesions - how big is the problem? Ann. R. Coll. Surg. Engl. 1990; 72: 60-3.
2. Chegini N. Peritoneal molecular environment, adhesion formation and clinical implication. Front. Biosci. 2002; 7: 91-115.
3. Halcox JP, Deanfield JE. Beyond the laboratory: Clinical implications for statin pleiotropy. Circulation 2004; 109: 1142-8.
4. Asakage M, Tsuno NH, Kitayama J et al. 3-Hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest. Anticancer Drugs 2004; 15: 625-32.
5. Bobik A, Campbell JH. Vascular derived growth factors: Cell biology, pathophysiology and pharmacology. Pharmacol. Rev. 1993; 45: 1-42.
6. Bucelli RC, Gonsiorek EA, Kim W-Y et al. Statins decrease expression of proinflammatory neuropeptides calcitonin gene-related peptide and substance P in sensory neurons. J. Pharmacol. Exp. Ther. 2008; 324: 1172-80.
7. Chen H, Ikeda U, Shimpo M, Ikeda M, Minota S, Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 2000; 36: 923-8.
8. Vincent L, Chen W, Hong L et al. Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: Contribution to its anti-angiogenic effect. FEBS Lett. 2001; 495: 159-66.
9. Vincent L, Soria C, Mirshahi F et al. Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaril coenzyme a reductase inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 623-9.
10. Aarons CB, Cohen PA, Gower A et al. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann. Surg. 2007; 245: 176-84.
11. Araújo FA, Rocha MA, Mendes JB, Andrade SP. Atorvastatin inhibits inflammatory angiogenesis in mice through down regulation of VEGF, TNF-alpha and TGF-beta1. Biomed. Pharmacother. 2010; 64: 29-34.
12. Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O. Hsp 90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res. 2001; 89: 866-73.
13. Kureishi Y, Luo Z, Shiojima I et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat. Med. 2000; 6: 1004-10.
14. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D, Galper JB. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 2002; 91: 143-50.
15. Urbich C, Dernbach E, Zeiher AM, Dimmeler S. Double-edge role of statins in angiogenesis signaling. Circ. Res. 2002; 90: 737-44.
16. Bogdan C. Nitric oxide and the immune response. Nat. Immunol. 2001; 2: 907-16.
17. Mendes JB, Campos PP, Ferreira MA, Bakhle YS, Andrade SP. Host response to sponge implants differs between subcutaneous and intraperitoneal sites in mice. J. Biomed. Mater. Res. Part B Appl. Biomater. 2007; 83: 408-15.
18. Mendes JB, Rocha MA, Araújo FA, Moura SA, Ferreira MA, Andrade SP. Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice. Microv. Res. 2009; 78: 265-71.
19. O'Brien PJ. Peroxidases. Chem. Biol. Interact. 2000; 18: 811-16.
20. Young PR, Karanutilake C, Zygas AP. Binding of cathepsin D to the mannose receptor on rat peritoneal macrophages. Biochim. Biophys. Acta 1991; 1095: 1-4.
21. Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in tumor-associated neovasculature. Br. J. Pharmacol. 1992; 107: 1092-5.
22. Buttery LD, Springall DR, Andrade SP et al. Induction of nitric oxide synthase in the neo-vasculature of experimental tumours in mice. J. Pathol. 1993; 171: 311-19.
23. Kimura M, Kurose I, Russel J, Granger DN. Effects of fluvastatin on leukocyte-endothelial cell adhesion in hyperchlesterolemic rats. Arterioscler. Thromb. Vasc. Biol. 1997; 17: 1521-6.
24. Riad A, Bien S, Westermann D et al. Pretreatment with statin attenuates the cardiotoxicity of Doxorubicin in mice. Cancer Res. 2009; 69: 695-9.
25. Robinson AJ, Kashanin D, O'Dowd F, Fitzgerald K, Williams V, Walsh GM. Fluvastatin and lovastatin inhibit granulocyte macrophage-colony stimulating factor-stimulated human eosinophil adhesion to inter-cellular adhesion molecule-1 under flow conditions. Clin. Exp. Allergy 2009; 39: 1866-74.
26. Romano M, Diomede L, Sironi M et al. Inhibition of monocyte chemotactic protein-1 synthesis by statins. Lab. Invest. 2000; 80: 1095-100.
27. Wang HR, Li JJ, Huang CX, Jiang H. Fluvastatin inhibits the expression of tumor necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reative protein. Clin. Chim. Acta 2005; 353: 53-60.
28. Weis M, Heeschen C, Glassford AJ, Cooke JP. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
29. Kim JW, Rhee CK, Kim TJ et al. Effect of pravastatin on bleomycin-induced acute lung injury and pulmonary fibrosis. Clin. Exp. Pharmacol. Physiol. 2010; 37: 1055-63.
30. Wilson SH, Herrmann J, Lerman LO et al. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-18.
31. Hillyard DZ, Jardine AG, Mcdonald KJ, Cameron AJ. Fluvastatin inhibits raft dependent Fcgamma receptor signaling in human monocytes. Atherosclerosis 2004; 172: 219-28.
32. Bitto A, Minutoli L, Altavilla D et al. Simvastatin enhances VEGF production and ameliorates impaired wound healing in experimental diabetes. Pharmacol. Res. 2008; 57: 159-69.
33. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J. Biol. Chem. 1997; 272: 31725-9.
34. Shears LL, Kawaharada N, Tzeng E et al. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J. Clin. Invest. 1997; 100: 2035-42.
35. Darra E, Rungatscher A, De Patri AC et al. Dual modulation of NO production in the heart during ischaemia/reperfusion injury and inflammation. Thromb. Haemost. 2010; 104: 200-6.